trending Market Intelligence /marketintelligence/en/news-insights/trending/siqnlqyedlj4oseoqcmjya2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

CCM Duopharma to buy 8.39% equity stake in PanGen Biotech

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CCM Duopharma to buy 8.39% equity stake in PanGen Biotech

Malaysia's CCM Duopharma Biotech Bhd. agreed to buy an 8.39% equity stake in South Korea-based PanGen Biotech Inc. for 59.2 million ringgit in cash.

PanGen Biotech develops biosimilars and provides services related to the development of biosimilar products. The Korean company also manufactures protein reagents along with assay kits and systems.

CCM will acquire 806,450 common shares in PanGen at 73.35 ringgit in cash per share.

Closing of the transaction will occur in the second quarter, subject to CCM shareholders' approval and other customary closing conditions.

Through the acquisition, CCM expects to enter the biotherapeutics medicine market with a lower cost by partnering with PanGen in developing its existing pipeline.

CCM Duopharma is engaged in the manufacture and distribution of pharmaceutical products and medicines.

As of June 13, US$1 was equivalent to 3.98 ringgit.